Reata Pharma (RETA) Prices 5.5M Class A Common Stock IPO at $11/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Reata Pharmaceuticals (RETA) IPO Opens Flat
May 26, 2016 10:39 AM EDTToday's IPO for Reata Pharmaceuticals, Inc. (Nasdaq: RETA) opened for trading at $11.06 after pricing 5,500,000 shares of its Class A common stock at $11.00 per share. The company was recently looking to offer 4 million shares and expected a pricing range of $14 - $16 per... More
